Plain-English translation of NCT05487170 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new medication called , which works by helping your body's natural defense system break down proteins that allow cancer cells to survive. The study is divided into two parts: first, doctors will find the safest and most effective dose by starting with small amounts and gradually increasing them; then, they will test this dose in larger groups of patients with specific cancer types to see how well the medication works.
Many patients with advanced cancers stop responding to standard treatments like chemotherapy, leaving them with limited options. This medication targets cancer cells in a new way, and researchers hope it could help patients whose tumors have become resistant to conventional therapies.
You likely qualify if…
You likely don't qualify if…
In the first part of the study, you will receive the medication through an IV infusion once a week for 3 weeks, followed by a week of rest—this pattern repeats as a 4-week cycle. Researchers will monitor your health closely and gradually increase the dose for later groups of patients until they find the best dose. In the second part, once the safest dose is identified, more patients will be enrolled to confirm how well the medication works against specific cancer types. Throughout the study, you will have regular clinic visits, blood tests, and imaging scans to check how your body is responding to the treatment.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
United States
China